The Bioventure partners TEAm


Vincent founded Pivotal bioVenture Partners in 2017 and Pivotal bioVenture Partners China in 2018.Vincent is also the Managing Director and the Chief Operating Officer of the Nan Fung Group, responsible for the Group’s strategic development as well as overall operations.
Mr. Cheung graduated from the University of California, Berkeley, graduating with honours in Molecular and Cell Biology.


Meng joined Nan Fung Group in 2015 and Pivotal China in 2018. Prior to joining Nan Fung Group, Meng was a Managing Director at Blackstone’s Private Equity Group in Hong Kong. At Blackstone, he was involved in a number of transactions across multiple industries. Before joining Blackstone, Meng was a Senior Vice President at Oaktree Capital Management, where he was involved in sourcing, structuring and executing private equity investments in China. Prior to that, Mr. Gao was an investment banker with Credit Suisse and JPMorgan in New York.

Meng received a Bachelor of Economics degree from Peking University, an M.A. from Yale University and an M.B.A. from the Wharton School of the University of Pennsylvania, where he graduated with Honours.


Shannon Cheung joined Pivotal China in 2018. He is also the Founder and Chief Executive Officer of Averest Capital, an investment company focusing on healthcare, TMT and environmental technology sectors, and Co-Founder and Vice Chairman of Likang Life Sciences. Shannon has participated in the investment of over 40 technology companies in China, including Alibaba Group, Hero Entertainment, VSPN, China Music Corporation (currently known as Tencent Music), CMGE, Yixin Group, Alltech Medical Systems, MChang, All Football, (China’s largest online continued education platform for doctors). Prior to Averest Capital, Shannon was Managing Director of global banking coverage in HSBC Markets (Asia) Limited and Chief Representative of HSBC (Securities Business) Beijing Representative Office, where he was responsible for business origination of investment banking in China, including IPOs and other equity related products, M&A advisory and high yield bond issuance.

Shannon is a member of the Chinese People’s Political Consultative Conference Shanghai Committee, Standing Committee member of All-China Youth Federation, Vice Chairman of All-China Financial Youth Federation, Standing Committee member of Central State-Owned Enterprise Youth Federation, Standing Committee member of Beijing Youth Federation and Founder and President of Fin Society, a non-profit professional fraternity aiming to enhance the competitiveness of finance practitioners in Hong Kong and nurture next-generation finance industry leaders. He is also a recipient of the Medal of Honour from the Government of Hong Kong.

Shannon holds a Bachelor of Commerce degree with distinction from the University of Calgary.


Dianna, joined Pivotal China in 2018 as a Partner. During the preceding 7 years, she worked at two well-established US dollar funds (Fidelity Asia Growth Partners and Foutainvest) as the core investment team members of their healthcare practice. Prior to that, Dianna was the Vice President at Boehringer Ingelheim China in charge of Corporate Strategy & Business Development and New Product Planning, where she led the strategic alliance of BI and Eli lily and licensed in several products in different therapeutic areas. Dianna started her career at BCG and later became an Engagement Manager at McKinsey’s China and US offices specializing in healthcare sector.
Dianna graduated from Wharton Business School with an MBA degree in 2004 and she also holds a Master degree and a BA degree in Finance from ECNU.


David joined Pivotal China in 2018. Prior to joining, he served as the Chief Business Officer at BioLineRx, a NASDAQ-traded drug development company where he was responsible for all licensing, M&A and strategic alliances. During his tenure he built partnerships between BioLineRx and several leading life sciences companies, including Novartis, Genentech and Merck, and led the in-licensing and acquisition of multiple pharmaceutical projects. Prior to his role at BioLineRx David was working for Sanofi in a variety of commercial and business development roles in the US and France, including BD&L, M&A, marketing and finance.

David gained his B.A. in statistics and political science at the University of Haifa, and his MBA at the Tuck School of Business at Dartmouth.


Lyndon joined Pivotal China and Nan Fung Life Sciences in 2018. Previously, Lyndon was President & Chief Executive Officer and member of the Board of Directors for Balance Therapeutics, a company developing drugs for rare, debilitating neurological diseases. He co-founded the company and led its growth from products in preclinical development to the completion of multiple Phase 1 and 2 trials across three indications. Prior, Lyndon was Vice President of Corporate Strategy and Alliances at Elan Pharmaceuticals and was responsible for strategic planning, product planning and business development. As Director of Technology Planning at ALZA, a specialty pharmaceutical company of Johnson & Johnson, he led technology strategy and guided new product planning teams. He was a Principal at the venture capital company Coastview Capital and led and supported successful investments in early stage biopharmaceutical and research tool companies. He was also a management consultant at McKinsey & Company and a leader in the Pharmaceutical and Medical Products Practice. He provided direction to senior executives of leading healthcare companies on business strategy, R&D strategy, operations, new business creation, mergers/acquisitions, and product commercialization.

Lyndon has an A.B. in Biochemical Sciences from Harvard University, an M.B.A. from MIT Sloan School of Management and a Ph.D. in Genetics from Harvard University.


June joined Pivotal China as an Operating Partner in 2018.  June is a business executive with 20 years of experience working for multinational biopharmaceutical companies in a variety of markets including the United States, China and Asia.  Prior to joining Pivotal China, June was the general manager of Celgene China (later acquired by BeiGene).  Before that she spent 17 years working at Eli Lilly & Company in different marketing and sales roles in the US and global teams, General Manger in Lilly Hong Kong, Marking Director in Lilly Mid-Sized Asia Markets, and VP of Lilly China leading its Biomedicines Business Unit.   With diverse functional and therapeutic experiences, June has the ability to build/grow successful organizations and lead turn-arounds.  Her business expertise covers a wide variety of therapeutic areas including specialty care areas such as hematology and oncology, as well as primary care areas including Neuroscience, Diabetes, Infectious Diseases, Osteoporosis, and Mens Health. 

June holds an M.B.A. and a M.S. degree in Biochemistry, both from the University of Maryland in the US, and a B.S. degree in Polymer Engineering from Shanghai Jiao Tong University in China.